This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferguson, J. J. Search for Related Content PubMed PubMed Citation Articles by Ferguson, J. J. Pubmed/NCBI databases Medline Plus Health Information Heart Diseases

(Circulation. 1996;93:843-846.)
© 1996 American Heart Association, Inc.

Articles

Meeting Highlights

American Heart Association 68th Scientific Sessions, Anaheim, California, November 13 to 15, 1995

James J. Ferguson, MD

From St Luke's Episcopal Hospital, Texas Heart Institute, Baylor College of Medicine, University of Texas Health Science Center at Houston.

	TIMI 9B: Heparin Versus Hirudin as Adjunctive Therapy for Thrombolysis in Acute Myocardial Infarction

 
Dr Elliott Antman, of Harvard Medical School and Brigham and Women's Hospital in Boston, Massachusetts, presented the results of the Thrombolysis in Myocardial Infarction (TIMI) 9B study at a Satellite Symposium sponsored by George Washington University immediately prior to the American Heart Association Meetings in Anaheim, California, in November 1995. The TIMI 9 trial was a randomized, double-blind study conducted in 150 clinical centers that was designed to compare the efficacy and safety of intravenous heparin versus the direct-acting thrombin inhibitor hirudin in patients with acute myocardial infarction (<12 hours from onset) treated with a thrombolytic agent (streptokinase or tissue-type plasminogen activator [TPA], at the discretion of the treating physician). The TIMI 9A study (n=757) was suspended in April 1994 because of excessive bleeding in both the heparin and hirudin groups. The TIMI 9B trial was restarted in May 1994 with lower doses of both heparin and hirudin; enrollment (n=3002) continued through August 1995. The primary end point of the study was the 30-day incidence of death, myocardial infarction, congestive heart failure, and shock. At 30 days, there was no significant difference in the primary end point between heparin (11.8%) and hirudin (12.8%) and no difference in the incidence of death and myocardial infarction (9.3% in the heparin group, 9.6% in the hirudin group). Similarly, there was no significant difference in major bleeding events (including intracranial hemorrhage) between treatment groups.

The TIMI 9 Investigators concluded that hirudin was equally effective as but not superior to heparin with respect to either . . . [Full Text of this Article]

This article has been cited by other articles:

				M. A. Hlatky, W. J. Rogers, I. Johnstone, D. Boothroyd, M. M. Brooks, B. Pitt, G. Reeder, T. Ryan, H. Smith, P. Whitlow, et al. Medical Care Costs and Quality of Life after Randomization to Coronary Angioplasty or Coronary Bypass Surgery N. Engl. J. Med., January 9, 1997; 336(2): 92 - 99. [Abstract] [Full Text] [PDF]

				L. Pilote, D. P. Miller, R. M. Califf, J. S. Rao, W. D. Weaver, and E. J. Topol Determinants of the Use of Coronary Angiography and Revascularization after Thrombolysis for Acute Myocardial Infarction N. Engl. J. Med., October 17, 1996; 335(16): 1198 - 1205. [Abstract] [Full Text] [PDF]